We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Quorum Health Corporation | NYSE:QHC | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.3044 | 0 | 01:00:00 |
Quorum Health Corporation (NYSE: QHC) (the “Company”) today announced its operating and financial results for the three and six months ended June 30, 2017.
Net operating revenues for the three months ended June 30, 2017 increased $0.4 million to $530.1 million, compared to $529.7 million for the same period in 2016. Net operating revenues for the quarter were negatively impacted by a decrease of $18.2 million from the four hospitals divested in December 2016 and in the first half of 2017, and a decrease of $11.3 million resulting from the Company’s inability to accrue in the 2017 period for the California Hospital Quality Assurance Fee (“HQAF”) program revenues for the 2017 to 2019 program period pending approval by Centers for Medicare & Medicaid Services (“CMS”). Excluding these amounts in both periods, net operating revenues increased $29.9 million for the three months ended June 30, 2017 compared to the same period in 2016, primarily due to favorable volume and rate variances and a decrease in the provision for bad debts. Net loss attributable to Quorum Health Corporation for the three months ended June 30, 2017 was $(30.6) million, or $(1.09) per share, compared to $(245.1) million, or $(8.63) per share, for the same period in 2016. The net loss for the three months ended June 30, 2017 was impacted by an $8.6 million decrease, net of provider taxes, related to the California HQAF program and $12.9 million of impairment charges related to the ten hospitals identified for potential divestiture. The Company’s 2016 results for the same period included $250.4 million of impairment charges. On a same-facility basis, as defined in footnote (j), the Company’s operating results for the three months ended June 30, 2017 reflect a 1.5% decrease in admissions and a 0.2% decrease in adjusted admissions compared to the same period in 2016. Excluding the four divested hospitals and ten hospitals intended for divestiture, admissions and adjusted admissions increased 1.5% and 2.6%, respectively, for these same periods.
Adjusted EBITDA for the three months ended June 30, 2017 was $34.4 million, compared to $29.2 million for the same period in 2016. Adjusted EBITDA was negatively impacted by the Company’s inability to accrue for the California HQAF program in the 2017 period, as stated above. Adjusted EBITDA for the three months ended June 30, 2016 included $8.6 million related to this program. The divested hospitals negatively impacted EBITDA by $4.7 million and $6.1 million for the three months ended June 30, 2017 and 2016, respectively. As a result, Adjusted EBITDA, Adjusted for Divestitures, was $39.1 million and $35.3 million for the three months ended June 30, 2017 and 2016, respectively.
Net operating revenues for the six months ended June 30, 2017 decreased $21.5 million to $1,057.8 million, compared to $1,079.3 million for the same period in 2016. Net operating revenues decreased $31.5 million related to the divested hospitals and decreased $22.3 million due to the inability to accrue revenues related to the California HQAF program, as discussed above. Excluding these amounts, net operating revenues of the remaining hospitals increased $32.3 million for the six months ended June 30, 2017 compared to the same period in 2016, primarily due to favorable volume and rate variances and a decrease in the provision for bad debts. Net loss attributable to Quorum Health Corporation for the six months ended June 30, 2017 was $(58.2) million, or $(2.08) per share, compared to $(250.1) million, or $(8.80) per share, for the same period in 2016. The 2017 period included impairment charges of $16.2 million related to hospitals held for sale or identified for potential divestiture and a net gain of $5.2 million on the sale of hospitals. The 2016 period included $250.4 million of impairment charges mentioned above, $16.9 million in revenues, net of provider taxes, related to the California HQAF program and $4.9 million of transaction costs related to the Spin-off. On a same-facility basis, the Company’s operating results for the six months ended June 30, 2017 reflect a 1.8% decrease in admissions and a 0.5% decrease in adjusted admissions compared to the same period in 2016. Excluding divested hospitals and hospitals intended for divestiture, admissions and adjusted admissions increased 0.4% and 1.4%, respectively, for these same periods.
Adjusted EBITDA for the six months ended June 30, 2017 was $60.6 million, compared to $85.5 million for the same period in 2016. Adjusted EBITDA was negatively impacted by the Company’s inability to accrue for the California HQAF program in the 2017 period, as stated above. Adjusted EBITDA for the six months ended June 30, 2016 included $16.9 million related to this program. The two hospitals divested in December 2016, in addition to the two hospitals divested in 2017, negatively impacted EBITDA by $6.7 million and $9.4 million for the six months ended June 30, 2017 and 2016, respectively. As a result, Adjusted EBITDA, Adjusted for Divestitures, was $67.2 million and $94.9 million for the six months ended June 30, 2017 and 2016, respectively. The Company had combined proceeds from these four divestitures of $34.0 million, of which $22.4 million was utilized to pay down the Company’s term loan under its credit facility.
Commenting on the results, Thomas D. Miller, president and chief executive officer of Quorum Health Corporation, said, “We believe the second quarter results demonstrate our commitment to improve operations. Our strategy to divest underperforming hospitals will improve our financial position. Our plan is to complete additional divestitures during the third quarter resulting in continued reductions in debt levels. We believe our financial operations will also benefit from improvements in billing and collections processes, resulting from our focused efforts in this area. We have dedicated our remaining core markets to quality and the expansion of service capabilities to improve volume growth and enhance profitability.”
Financial Outlook
The Company’s updated financial outlook for the year ending December 31, 2017 is discussed below. These projections update selected guidance issued on March 29, 2017 and are based on the Company’s historical operating performance, current economic, demographic and regulatory trends and other assumptions that the Company believes are reasonable at this time. The 2017 guidance should be considered in conjunction with the assumptions included herein. See “Forward-Looking Statements” below for a list of factors that could affect the future results of the Company or the healthcare industry generally.
The Company expects net operating revenues for the year ending December 31, 2017 to range from $2.050 billion to $2.100 billion. The Company expects Adjusted EBITDA for the year ending December 31, 2017 to range from $150 million to $170 million and Adjusted EBITDA, Adjusted for Potential Divestitures to range from $170 million to $190 million. The guidance gives effect to: (i) divestitures and potential divestitures stated above, (ii) the approval of the California Department of Health Care Services’ HQAF Program by CMS, which we estimate to be approved in the fourth quarter of 2017 at approximately $21 million, approximately $13 million less than 2016, (iii) the reduction of approximately $7 million in electronic health records incentives earned in 2017 compared to the 2016 amounts, (iv) the inclusion of approximately $10 million to $13 million of non-cash stock-based compensation and other non-cash benefits expense and approximately $25 million to $26 million of non-cash insurance expense, and (v) no estimate for the effects of any changes to the Affordable Care Act. Adjusted EBITDA, Adjusted for Potential Divestitures includes the same assumptions above, in addition to excluding the negative EBITDA of the potential divestitures from the beginning of the year. A reconciliation of the Company’s projected 2017 Adjusted EBITDA, and Adjusted EBITDA, Adjusted for Potential Divestitures, each a forward-looking non-GAAP financial measure, to net income (loss), the most directly comparable U.S. GAAP financial measure, is omitted from this press release because the Company is unable to provide such reconciliation without unreasonable effort. This inability results from the inherent difficulty in forecasting generally and in quantifying certain projected amounts that are necessary for such reconciliation.
In particular, sufficient information is not available to calculate certain adjustments required for such reconciliation without unreasonable effort, including interest expense, income tax expense (benefit) and other adjustments that would be necessary to prepare a forward-looking statement of net income (loss) in accordance with U.S. GAAP. For the same reasons, the Company is unable to address the probable significance of the unavailable information.
About Quorum Health Corporation
The principal business of Quorum Health Corporation is to provide hospital and outpatient healthcare services in its markets across the United States. As of June 30, 2017, the Company owned or leased 34 hospitals in rural and mid-sized markets located across 16 states and licensed for 3,168 beds. Through Quorum Health Resources LLC, a wholly-owned subsidiary, the Company provides hospital management advisory and healthcare consulting services. Over 95% of the Company’s net operating revenues are attributable to its hospital operations business.
The Company’s headquarters are located in Brentwood, Tennessee, a suburb south of Nashville. Shares in Quorum Health Corporation are traded on the NYSE under the symbol “QHC.” More information about the Company can be found on its website at www.quorumhealth.com.
Quorum Health Corporation will hold a conference call on Thursday, August 10, 2017, 10:00 a.m. Central time, 11:00 a.m. Eastern, to review operating and financial results for the three and six months ended June 30, 2017. Investors will have the opportunity to listen to a live internet broadcast of the conference call by clicking on the Investor Relations link of the Company’s website at www.quorumhealth.com. To listen to the live call, please go to the website at least 15 minutes early to register, download and install any necessary audio software. For those who cannot listen to the live broadcast, a replay will be available shortly after the call and will continue to be available for approximately 30 days. Copies of this press release and the Company’s Current Report on Form 8-K (including this press release) are available on the Company’s website at www.quorumhealth.com.
QUORUM HEALTH CORPORATION UNAUDITED CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF INCOME (LOSS) (In Thousands, Except Earnings per Share and Shares) Three Months Ended June 30, 2017 2016 % of % of $ Amount Revenues $ Amount Revenues Operating revenues, net of contractual allowances and discounts (a) $ 585,215 $ 598,163 Provision for bad debts 55,069 68,426 Net operating revenues 530,146 100.0 % 529,737 100.0 % Operating costs and expenses: Salaries and benefits 265,309 50.0 % 264,886 50.0 % Supplies 64,112 12.1 % 64,136 12.1 % Other operating expenses (a) 157,613 29.8 % 163,185 30.8 % Depreciation and amortization 20,586 3.9 % 31,463 5.9 % Rent 12,152 2.3 % 12,545 2.4 % Electronic health records incentives earned (1,777 ) (0.3 )% (4,247 ) (0.8 )% Legal, professional and settlement costs 3,934 0.7 % 5,447 1.0 % Impairment of long-lived assets and goodwill 12,900 2.4 % 250,400 47.3 % Loss (gain) on sale of hospitals, net (4,321 ) (0.8 )% — — % Transaction costs related to the Spin-off — — % 1,177 0.2 % Total operating costs and expenses 530,508 100.1 % 788,992 148.9 % Income (loss) from operations (362 ) (0.1 )% (259,255 ) (48.9 )% Interest expense, net 30,458 5.7 % 29,276 5.6 % Income (loss) before income taxes (30,820 ) (5.8 )% (288,531 ) (54.5 )% Provision for (benefit from) income taxes (245 ) — % (44,565 ) (8.4 )% Net income (loss) (b) (30,575 ) (5.8 )% (243,966 ) (46.1 )% Less: Net income (loss) attributable to noncontrolling interests 55 — % 1,095 0.2 % Net income (loss) attributable to Quorum Health Corporation $ (30,630 ) (5.8 )% $ (245,061 ) (46.3 )% Earnings (loss) per share attributable to Quorum Health Corporation stockholders: Basic and diluted (c) $ (1.09 ) $ (8.63 ) Weighted-average shares outstanding: Basic and diluted (d) 28,145,215 28,412,720For footnotes, see pages 8-10.
QUORUM HEALTH CORPORATION UNAUDITED CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF INCOME (LOSS) (In Thousands, Except Earnings per Share and Shares) Six Months Ended June 30, 2017 2016 % of % of $ Amount Revenues $ Amount Revenues Operating revenues, net of contractual allowances and discounts (a) $ 1,173,160 $ 1,212,647 Provision for bad debts 115,374 133,359 Net operating revenues 1,057,786 100.0 % 1,079,288 100.0 % Operating costs and expenses: Salaries and benefits 529,911 50.1 % 521,748 48.3 % Supplies 127,934 12.1 % 127,797 11.8 % Other operating expenses (a) 321,037 30.4 % 327,648 30.5 % Depreciation and amortization 42,706 4.0 % 62,620 5.8 % Rent 24,254 2.3 % 25,094 2.3 % Electronic health records incentives earned (4,229 ) (0.4 )% (8,455 ) (0.8 )% Legal, professional and settlement costs 4,469 0.4 % 5,688 0.5 % Impairment of long-lived assets and goodwill 16,200 1.5 % 250,400 23.2 % Loss (gain) on sale of hospitals, net (5,191 ) (0.5 )% — — % Transaction costs related to the Spin-off 31 — % 4,912 0.5 % Total operating costs and expenses 1,057,122 99.9 % 1,317,452 122.1 % Income (loss) from operations 664 0.1 % (238,164 ) (22.1 )% Interest expense, net 57,988 5.5 % 56,728 5.2 % Income (loss) before income taxes (57,324 ) (5.4 )% (294,892 ) (27.3 )% Provision for (benefit from) income taxes 456 0.1 % (46,239 ) (4.3 )% Net income (loss) (b) (57,780 ) (5.5 )% (248,653 ) (23.0 )% Less: Net income (loss) attributable to noncontrolling interests 411 — % 1,410 0.2 % Net income (loss) attributable to Quorum Health Corporation $ (58,191 ) (5.5 )% $ (250,063 ) (23.2 )% Earnings (loss) per share attributable to Quorum Health Corporation stockholders: Basic and diluted (c) $ (2.08 ) $ (8.80 ) Weighted-average shares outstanding: Basic and diluted (d) 27,977,738 28,412,389For footnotes, see pages 8-10.
QUORUM HEALTH CORPORATION UNAUDITED CONSOLIDATED AND COMBINED SELECTED OPERATING DATA Three Months Ended June 30, 2017 2016 Variance % Variance Consolidated and combined: Number of licensed beds at end of period (e) 3,168 3,579 (411 ) (11.5 )% Admissions (f) 22,270 23,618 (1,348 ) (5.7 )% Adjusted admissions (g) 55,634 58,942 (3,308 ) (5.6 )% Emergency room visits (h) 167,575 182,301 (14,726 ) (8.1 )% Medicare case mix index (i) 1.43 1.38 0.05 3.6 % Same-facility: (j) Number of licensed beds at end of period (e) 3,168 3,168 — — % Admissions (f) 22,270 22,617 (347 ) (1.5 )% Adjusted admissions (g) 55,634 55,730 (96 ) (0.2 )% Emergency room visits (h) 167,575 171,779 (4,204 ) (2.4 )% Medicare case mix index (i) 1.41 1.39 0.02 1.4 % Six Months Ended June 30, 2017 2016 Variance % Variance Consolidated and combined: Number of licensed beds at end of period (e) 3,168 3,579 (411 ) (11.5 )% Admissions (f) 45,926 48,610 (2,684 ) (5.5 )% Adjusted admissions (g) 112,501 118,746 (6,245 ) (5.3 )% Emergency room visits (h) 340,514 367,235 (26,721 ) (7.3 )% Medicare case mix index (i) 1.41 1.37 0.04 2.9 % Same-facility: (j) Number of licensed beds at end of period (e) 3,168 3,168 — — % Admissions (f) 45,708 46,550 (842 ) (1.8 )% Adjusted admissions (g) 111,763 112,346 (583 ) (0.5 )% Emergency room visits (h) 338,464 345,973 (7,509 ) (2.2 )% Medicare case mix index (i) 1.40 1.38 0.02 1.4 %For footnotes, see pages 8-10.
QUORUM HEALTH CORPORATION UNAUDITED CONDENSED CONSOLIDATED AND COMBINED BALANCE SHEETS (In Thousands, Except Par Value per Share and Shares) June 30, December 31, 2017 2016 ASSETS Current assets: Cash and cash equivalents $ 22,405 $ 25,455 Patient accounts receivable, net of allowance for doubtful accounts of $340,197 and $360,796 at June 30, 2017 and December 31, 2016, respectively 409,217 380,685 Inventories 54,269 58,124 Prepaid expenses 27,641 23,028 Due from third-party payors 97,172 116,235 Current assets of hospitals held for sale 5,813 1,502 Other current assets 48,329 57,942 Total current assets 664,846 662,971 Property and equipment, at cost 1,436,407 1,519,975 Less: Accumulated depreciation and amortization (724,929 ) (786,075 ) Total property and equipment, net 711,478 733,900 Goodwill 409,781 416,833 Intangible assets, net 77,694 84,982 Long-term assets of hospitals held for sale 14,381 6,851 Other long-term assets 109,321 88,833 Total assets $ 1,987,501 $ 1,994,370 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ 1,649 $ 5,683 Accounts payable 170,862 169,684 Accrued liabilities: Accrued salaries and benefits 94,381 98,803 Accrued interest 10,142 19,915 Due to third-party payors 38,881 42,537 Current liabilities of hospitals held for sale 1,391 492 Other current liabilities 47,163 53,268 Total current liabilities 364,469 390,382 Long-term debt 1,284,721 1,241,142 Deferred income tax liabilities, net 31,729 31,474 Other long-term liabilities 141,756 108,996 Total liabilities 1,822,675 1,771,994 Redeemable noncontrolling interests 5,614 6,807 Equity: Quorum Health Corporation stockholders' equity: Preferred stock, $0.0001 par value per share, 100,000,000 shares authorized, none issued — — Common stock, $0.0001 par value per share, 300,000,000 shares authorized; 30,297,524 shares issued and outstanding at June 30, 2017, and 29,482,050 shares issued and outstanding at December 31, 2016 3 3 Additional paid-in capital 541,774 537,911 Accumulated other comprehensive income (loss) (2,518 ) (2,760 ) Accumulated deficit (392,217 ) (334,026 ) Total Quorum Health Corporation stockholders' equity 147,042 201,128 Nonredeemable noncontrolling interests 12,170 14,441 Total equity 159,212 215,569 Total liabilities and equity $ 1,987,501 $ 1,994,370For footnotes, see pages 8-10.
QUORUM HEALTH CORPORATION UNAUDITED CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS (In Thousands) Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Cash flows from operating activities: Net income (loss) $ (30,575 ) $ (243,966 ) $ (57,780 ) $ (248,653 ) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 20,586 31,463 42,706 62,620 Non-cash interest expense 700 729 1,430 729 Provision for (benefit from) deferred income taxes (346 ) (47,451 ) 255 (47,451 ) Stock-based compensation expense 2,531 1,897 5,328 1,897 Impairment of long-lived assets and goodwill 12,900 250,400 16,200 250,400 Loss (gain) on sale of hospitals, net (4,321 ) — (5,191 ) — Changes in reserves for self-insurance claims, net of payments 7,042 8,901 11,254 16,891 Changes in reserves for legal, professional and settlement costs, net of payments — 4,642 (3,651 ) 4,642 Other non-cash expense (income), net 47 (33 ) 5 (587 ) Changes in operating assets and liabilities, net of acquisitions and divestitures: Patient accounts receivable, net (13,186 ) 4,911 (30,349 ) (7,211 ) Due from and due to third-party payors, net 4,366 (6,538 ) 15,407 5,355 Inventories, prepaid expenses and other current assets 8,942 5,103 (7,732 ) 2,277 Accounts payable and accrued liabilities (36,773 ) 36,072 1,292 29,129 Long-term assets and liabilities, net 606 (9,334 ) 1,871 (8,845 ) Net cash provided by (used in) operating activities (27,481 ) 36,796 (8,955 ) 61,193 Cash flows from investing activities: Capital expenditures for property and equipment (15,925 ) (20,367 ) (39,142 ) (33,207 ) Capital expenditures for software (1,663 ) (1,278 ) (3,169 ) (3,804 ) Acquisitions, net of cash acquired (1,887 ) — (1,887 ) — Proceeds from the sale of hospitals 15,874 — 20,156 — Other investing activities — 492 — 1,402 Net cash provided by (used in) investing activities (3,601 ) (21,153 ) (24,042 ) (35,609 ) Cash flows from financing activities: Borrowings (repayments) of revolving credit facilities, net (28,000 ) — 50,000 — Borrowings of long-term debt 72 1,255,500 72 1,255,520 Repayments of long-term debt (4,738 ) (3,188 ) (11,847 ) (4,277 ) Increase (decrease) in Due to Parent, net — 31,669 — 25,183 Payments of debt issuance costs (2,891 ) (28,003 ) (2,938 ) (28,003 ) Cash paid to Parent related to the Spin-off — (1,217,336 ) — (1,217,336 ) Cancellation of restricted stock awards for payroll tax withholdings on vested shares (461 ) 27 (1,489 ) 27 Cash distributions to noncontrolling investors (37 ) (163 ) (3,851 ) (2,647 ) Purchases of shares from noncontrolling investors — — — (12 ) Net cash provided by (used in) financing activities (36,055 ) 38,506 29,947 28,455 Net change in cash and cash equivalents (67,137 ) 54,149 (3,050 ) 54,039 Cash and cash equivalents at beginning of period 89,542 996 25,455 1,106 Cash and cash equivalents at end of period $ 22,405 $ 55,145 $ 22,405 $ 55,145For footnotes, see pages 8-10.
FOOTNOTES TO UNAUDITED FINANCIAL STATEMENTS AND SELECTED OPERATING DATA
(a) The California Department of Health Care Services implemented the HQAF program, imposing a fee on certain general and acute care California hospitals. Revenues generated from these fees provide funding for the non-federal supplemental payments to California hospitals that serve California’s Medicaid (“Medi-Cal”) and uninsured patients. Under the most recent phase of the program, covering the period January 2014 through December 2016, the Company recognized $11.3 million of net operating revenues less $2.7 million of provider taxes for the three months ended June 30, 2016. The Company recognized $22.3 million of net operating revenues less $5.4 million of provider taxes for the six months ended June 30, 2016. There were no comparative amounts recorded in the 2017 periods, as discussed below. In November 2016, California voters approved a state constitutional amendment measure that extends indefinitely the statute that imposes fees on California hospitals seeking federal matching funds. However, the current program expired on December 31, 2016 and CMS has not approved a new program. Consistent with the first four phases of the HQAF program, the Company does not recognize any revenues under the new program until CMS completes the approval process. HQAF funding levels are based in part on Medi-Cal utilization. As a result, changes in coverage of individuals under the Medi-Cal program could affect the revenues and cash flows related to the Company’s California hospitals under future phases of the HQAF program. Accordingly, the Company is unable to predict the ultimate amount of revenues and cash flows its California hospitals may receive from or the timing of CMS’ approval of the extended HQAF program, including its impact on the Company’s 2017 quarterly or full year net operating results. The Company has included an estimated amount in its 2017 projections based on currently available and historical information. (b) EBITDA is a non-GAAP financial measure that consists of net income (loss) before interest, income taxes, depreciation and amortization. Adjusted EBITDA, also a non-GAAP financial measure, is EBITDA adjusted to add back the effect of certain legal, professional and settlement costs, impairment of long-lived assets and goodwill, net loss (gain) on sale of hospitals and transaction costs related to the Spin-off. The Company uses Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by the Company’s management to assess the operating performance of its hospital operations business and to make decisions on the allocation of resources. Additionally, management utilizes Adjusted EBITDA in assessing the Company’s consolidated results of operations and in comparing the Company’s results of operations between periods. Adjusted EBITDA, Adjusted for Divestitures, also a non-GAAP financial measure, is further retrospectively adjusted to exclude the effect of EBITDA of hospitals divested in December 2016 and in 2017. The Company has presented Adjusted EBITDA and Adjusted EBITDA, Adjusted for Divestitures in this press release because it believes these measures provide investors and other users of the Company’s financial statements with additional information about how the Company’s management assesses its results of operations. Adjusted EBITDA and Adjusted EBITDA, Adjusted for Divestitures are not measurements of financial performance under U.S. GAAP. These calculations should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with U.S. GAAP. The items excluded from Adjusted EBITDA and Adjusted EBITDA, Adjusted for Divestitures are significant components in understanding and evaluating the Company’s financial performance. The Company believes such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Additionally, the Company’s calculation of Adjusted EBITDA and Adjusted EBITDA, Adjusted for Divestitures may not be comparable to similarly titled measures reported by other companies. FOOTNOTES TO UNAUDITED FINANCIAL STATEMENTS AND SELECTED OPERATING DATA (Continued)The following table reconciles Adjusted EBITDA and Adjusted EBITDA, Adjusted for Divestitures, each as defined above, to net income (loss), the most directly comparable U.S. GAAP financial measure, as derived directly from the Company’s consolidated and combined financial statements for the respective periods (in thousands):
Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Net income (loss) $ (30,575 ) $ (243,966 ) $ (57,780 ) $ (248,653 ) Interest expense, net 30,458 29,276 57,988 56,728 Provision for (benefit from) income taxes (245 ) (44,565 ) 456 (46,239 ) Depreciation and amortization 20,586 31,463 42,706 62,620 EBITDA 20,224 (227,792 ) 43,370 (175,544 ) Legal, professional and settlement costs 3,934 5,447 4,469 5,688 Impairment of long-lived assets and goodwill 12,900 250,400 16,200 250,400 Loss (gain) on sale of hospitals, net (4,321 ) — (5,191 ) — Transaction costs related to the Spin-off — 1,177 31 4,912 Post-spin headcount reductions 1,693 — 1,693 — Adjusted EBITDA 34,430 29,232 60,572 85,456 Negative EBITDA of divested hospitals 4,716 6,060 6,652 9,427 Adjusted EBITDA, Adjusted for Divestitures $ 39,146 $ 35,292 $ 67,224 $ 94,883(c)
The following table reconciles net income (loss) attributable to Quorum Health Corporation, as reported and on a per share basis, with the adjustments described herein:
Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (per share - basic and diluted) Earnings (loss) per share attributable to Quorum Health Corporation stockholders, as reported $ (1.09 ) $ (8.63 ) $ (2.08 ) $ (8.80 ) Adjustments: Legal, professional and settlement costs 0.14 0.16 0.16 0.17 Impairment of long-lived assets and goodwill 0.45 7.46 0.58 7.43 Loss (gain) on sale of hospitals, net (0.15 ) — 0.02 — Transaction costs related to the Spin-off — 0.04 — 0.15 Post-spin headcount reductions 0.06 — 0.06 — Net operating losses of divested hospitals 0.17 0.15 0.24 0.28 Earnings (loss) per share attributable to Quorum Health Corporation stockholders, excluding adjustments $ (0.42 ) $ (0.82 ) $ (1.02 ) $ (0.77 )FOOTNOTES TO UNAUDITED FINANCIAL STATEMENTS AND SELECTED OPERATING DATA
(Continued)
(d) For comparative purposes, the Company used 28,412,054 shares as the number of weighted-average shares to calculate basic and diluted earnings per share for periods prior to the Spin-off. This number represents the number of shares issued on the Spin-off date. Due to the net loss attributable to Quorum Health Corporation in the three and six months ended June 30, 2017, no incremental shares are included in diluted earnings per share for this period, because the effect of the incremental shares would be anti-dilutive. No incremental shares were considered for any periods prior to the Spin-off. (e) Licensed beds are the number of beds for which the appropriate state agency licenses a hospital, regardless of whether the beds are actually available for patient use. (f) Admissions represent the number of patients admitted for inpatient services. (g) Adjusted admissions is computed by multiplying admissions by gross patient revenues and then dividing that number by gross inpatient revenues. (h) Emergency room visits represent the number of patients registered and treated in the Company’s emergency rooms. (i) Medicare case mix index is a relative value assigned to a diagnosis-related group of inpatients that is used in determining the allocation of resources necessary to treat the patients in that group. Medicare case mix index is calculated as the average case mix index for all Medicare admissions during the period. (j) Same-facility financial and operating data includes hospitals that are owned and leased during all periods. Same-facility operating results have been adjusted to exclude the operating results of Sandhills Regional Medical Center, Barrow Regional Medical Center and Cherokee Medical Center which were sold on December 1, 2016, December 31, 2016 and March 31, 2017, respectively. Same-facility operating results includes the operating results of Trinity Hospital of Augusta, since this hospital was not sold until June 30, 2017.Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 that involve risk and uncertainties. All statements in this press release other than statements of historical fact, including statements regarding projections, expected operating results, and other events that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “thinks,” and similar expressions, are forward-looking statements. Although the Company believes that these forward-looking statements are based on reasonable assumptions, these assumptions are inherently subject to significant economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond the control of the Company. Accordingly, the Company cannot give any assurance that its expectations will in fact occur and cautions that actual results may differ materially from those in the forward-looking statements. A number of factors could affect the future results of the Company or the healthcare industry generally and could cause the Company’s expected results to differ materially from those expressed in this press release.
These factors include, but are not limited to, the following:
Although the Company believes that these forward-looking statements are based upon reasonable assumptions, these assumptions are inherently subject to significant regulatory, economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond its control. Accordingly, the Company cannot give any assurance that its expectations will in fact occur and cautions that actual results may differ materially from those in the forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are made as of the date of this filing. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170809006156/en/
Quorum Health CorporationMichael J. Culotta, 615-221-3502Executive Vice President and Chief Financial Officer
1 Year Quorum Health Chart |
1 Month Quorum Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions